Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-957 in mild Alzheimer's disease and MCI
NCT02573740Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) comparing ABT-957 with Placebo (2 arms). Primary endpoints: Percentage of participants reporting treatment-emergent adverse events at 84 days and Level of spectrin breakdown product-145 (SBDP-145) at 84 days. Started Dec 2015; status: terminated.
02
Drugs
alicapistat
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02573740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573740.